Bladder cancer is the fourth most commonly diagnosed cancer in men in the United States and the 10th leading cause of cancer deaths. Many treatments can be used for bladder cancer, and the kind of ...

Radical cystectomy, or complete bladder removal, remains the standard and most effective surgery for muscle‑invasive bladder ...

The European Medicines Agency (EMA)’s Committee for Medicinal Products for Human Use (CHMP) has recommended granting a conditional marketing authorization in the EU for Anktiva to treat adults with ...

Fox Chase Cancer Center researchers reported positive results from the trial, known as RETAIN-2, demonstrating that a response-adapted bladder-preservation approach involving neoadjuvant ...

Bladder cancer ranks among the ten most common types of cancer worldwide. The main treatment is bladder removal surgery, and despite advances in systemic therapies, recurrence is frequent in the most ...

NCCN now includes Anktiva plus BCG for BCG-unresponsive papillary-only NMIBC, acknowledging an unmet need in patients without ...

Circulating tumor DNA, or ctDNA, can predict metastatic risk in patients who receive bladder-sparing treatment for muscle-invasive bladder cancer, but it is not a good predictor of local recurrence ...

The U.S. Food and Drug Administration (FDA) has approved Inqlso (formerly Tar200) – an innovative local treatment for patients with bladder cancer of the carcinoma in situ (CIS) type that is resistant ...

Bladder cancer ranks among the ten most common types of cancer worldwide. The main treatment is bladder removal surgery, and despite advances in systemic therapies, recurrence is frequent in the most ...

The extent of the bladder cancer — how far it has spread — matters. Your care team needs to know if your cancer sits on or in the first lining of your bladder (non-muscle invasive), if it goes into ...